Small molecule TSHR agonists and antagonists;Le récepteur de TSH et les petites molécules: Les agonistes et les antagonistes

Annales d'Endocrinologie

Volumn 72, Issue 2, 2011, Pages 74-76

  Neumann, S ^a   Gershengorn, M C ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Graves' disease; Small molecule ligands; Thyroid; Thyroid cancer; TSH receptor

Indexed keywords

HORMONE RECEPTOR AFFECTING AGENT; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROID HORMONE; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR BLOCKING AGENT; THYROTROPIN RECEPTOR STIMULATING AGENT; THYROXINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG EFFECT; GRAVES DISEASE; HORMONE RECEPTOR INTERACTION; HUMAN; NONHUMAN; THYROID CANCER; THYROID FOLLICLE CELL; THYROID HORMONE RELEASE; THYROID HORMONE SYNTHESIS; THYROIDECTOMY; THYROXINE BLOOD LEVEL; TUMOR ABLATION;

ANIMALS; CELLS, CULTURED; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; GRAVES DISEASE; HUMANS; IODINE ISOTOPES; LIGANDS; MICE; RECEPTORS, THYROTROPIN; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; THYROID FUNCTION TESTS; THYROID GLAND; THYROID NEOPLASMS; THYROXINE;

EID: 79955721930     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2011.03.002     Document Type: Article

References (10)

1. Davies T.F., Ando T., Lin R.Y., Tomer Y., Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves' disease. J Clin Invest 2005, 115:1972-1983.
2. Neumann S., Raaka B.M., Gershengorn M.C. Development of human TSH receptor ligands as pharmacological probes and for potential clinical application. Expert Rev Endocrinol Metab 2009, 4:669-679.
3. Duntas L.H., Cooper D.S. Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. Thyroid 2008, 18:509-516.
4. Lee J., Yun M.J., Nam K.H., Chung W.Y., Soh E.Y., Park C.S. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 2010, 20:173-179.
5. Titus S., Neumann S., Zheng W., Southall N., Michael S., Klumpp C., et al. Quantitative high throughput screening using a live cell cAMP assay identifies small molecule agonists of the TSH receptor. J Biomol Screen 2008, 13:120-127.
6. Neumann S., Huang W., Titus S., Krause G., Kleinau G., Alberobello A.T., et al. Small molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. Proc Natl Acad Sci U S A 2009, 106:12471-12476.
7. Neumann S., Kleinau G., Costanzi S., Moore S., Jiang J.K., Raaka B.M., et al. A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinology 2008, 149:5945-5950.
8. Neumann S., Huang W., Eliseeva E., Titus S., Thomas C.J., Gershengorn M.C. A small molecule inverse agonist for the human TSH receptor. Endocrinology 2010, 151:3454-3459.
9. Neumann S, Eliseeva E, McCoy G, Napolitano G, Giuliani C, Monaco F, et al. A new small molecule antagonist inhibits Graves' disease antibody activation of the TSHR. J Clin Endocrinol Metab 2011;96:548-554.
10. Bond R.A., Ijzerman A.P. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci 2006, 27:92-96.